Journal
PHARMACEUTICS
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics11110614
Keywords
inflammation; macrophages; glucocorticoid; polymersomes
Categories
Funding
- ERC [StG-MEViC 278793, PoC-AIDViC 543379, CheSSTAG 769798]
- EPSRC [EP/N026322/1, EP/I001697/1]
- EPSRC [EP/K005030/1] Funding Source: UKRI
Ask authors/readers for more resources
Glucocorticoid (GC) drugs are the cornerstone therapy used in the treatment of inflammatory diseases. Here, we report pH responsive poly(2-methacryloyloxyethyl phosphorylcholine)-poly(2-(diisopropylamino)ethyl methacrylate) (PMPC-PDPA) polymersomes as a suitable nanoscopic carrier to precisely and controllably deliver GCs within inflamed target cells. The in vitro cellular studies revealed that polymersomes ensure the stability, selectivity and bioavailability of the loaded drug within macrophages. At molecular level, we tested key inflammation-related markers, such as the nuclear factor-kappa B, tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6. With this, we demonstrated that pH responsive polymersomes are able to enhance the anti-inflammatory effect of loaded GC drug. Overall, we prove the potential of PMPC-PDPA polymersomes to efficiently promote the inflammation shutdown, while reducing the well-known therapeutic limitations in GC-based therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available